» Articles » PMID: 28983411

Intestinal Microbiota: a Potential Target for the Treatment of Postmenopausal Osteoporosis

Overview
Journal Bone Res
Date 2017 Oct 7
PMID 28983411
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Postmenopausal osteoporosis (PMO) is a prevalent metabolic bone disease characterized by bone loss and structural destruction, which increases the risk of fracture in postmenopausal women. Owing to the high morbidity and serious complications of PMO, many efforts have been devoted to its prophylaxis and treatment. The intestinal microbiota is the complex community of microorganisms colonizing the gastrointestinal tract. Probiotics, which are dietary or medical supplements consisting of beneficial intestinal bacteria, work in concert with endogenous intestinal microorganisms to maintain host health. Recent studies have revealed that bone loss in PMO is closely related to host immunity, which is influenced by the intestinal microbiota. The curative effects of probiotics on metabolic bone diseases have also been demonstrated. The effects of the intestinal microbiota on bone metabolism suggest a promising target for PMO management. This review seeks to summarize the critical effects of the intestinal microbiota and probiotics on PMO, with a focus on the molecular mechanisms underlying the pathogenic relationship between bacteria and host, and to define the possible treatment options.

Citing Articles

Gut-X axis.

Lin X, Yu Z, Liu Y, Li C, Hu H, Hu J Imeta. 2025; 4(1):e270.

PMID: 40027477 PMC: 11865426. DOI: 10.1002/imt2.270.


Total flavonoids isolated from can alleviate bone loss and regulate intestinal microbiota in ovariectomized rats.

Yin B, Yang M, Wang B, Zhang Y, Li N, Li Q Front Pharmacol. 2025; 16:1513863.

PMID: 39989899 PMC: 11842935. DOI: 10.3389/fphar.2025.1513863.


Integrated metagenomic and metabolomic analyses of the effects of total flavonoids of Rhizoma Drynariae on reducing ovariectomized-induced osteoporosis by regulating gut microbiota and related metabolites.

Li Q, Wu X, Niu X, Yu Z, Fang S, Chu X PLoS One. 2025; 20(2):e0317832.

PMID: 39951448 PMC: 11828363. DOI: 10.1371/journal.pone.0317832.


Dual disease co-expression analysis reveals potential roles of estrogen-related genes in postmenopausal osteoporosis and Parkinson's disease.

Yu D, Kang J, Ju C, Wang Q, Qiao Y, Qiao L Front Genet. 2025; 15():1518471.

PMID: 39840278 PMC: 11747517. DOI: 10.3389/fgene.2024.1518471.


Mechanisms of gut homeostasis regulating Th17/Treg cell balance in PMOP.

Qi P, Xie R, Liu H, Zhang Z, Cheng Y, Ma J Front Immunol. 2024; 15:1497311.

PMID: 39735544 PMC: 11671525. DOI: 10.3389/fimmu.2024.1497311.


References
1.
Kantengwa S, Jornot L, Devenoges C, Nicod L . Superoxide anions induce the maturation of human dendritic cells. Am J Respir Crit Care Med. 2003; 167(3):431-7. DOI: 10.1164/rccm.200205-425OC. View

2.
Wu J, Oka J, Ezaki J, Ohtomo T, Ueno T, Uchiyama S . Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause. 2007; 14(5):866-74. DOI: 10.1097/gme.0b013e3180305299. View

3.
Bowey E, Adlercreutz H, Rowland I . Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem Toxicol. 2003; 41(5):631-6. DOI: 10.1016/s0278-6915(02)00324-1. View

4.
Thompson D, Simmons H, Pirie C, Ke H . FDA Guidelines and animal models for osteoporosis. Bone. 1995; 17(4 Suppl):125S-133S. DOI: 10.1016/8756-3282(95)00285-l. View

5.
Kashtanova D, Popenko A, Tkacheva O, Tyakht A, Alexeev D, Boytsov S . Association between the gut microbiota and diet: Fetal life, early childhood, and further life. Nutrition. 2016; 32(6):620-7. DOI: 10.1016/j.nut.2015.12.037. View